News & Insights
Stay up to date on PsychoGenics’ latest research, press releases, and industry developments in preclinical drug discovery. Combine our expertise with yours to spark the translational power of your next CNS breakthrough.
Filters
Filters
Therapeutic Areas
In Vivo AI Platforms
Mental Illness
Neurodegenerative Disorders
Neurodevelopmental Disorders
Neuromuscular Disorders
Pain
Sleep & Seizure Disorders
Rare CNS Disorders
Traumatic Brain Injury
Specific Disorders
Apply Filters
Filters
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
April 6, 2023
INDUSTRY NEWS
5 Women Leading the Way in Biotech
March 8, 2023
INDUSTRY NEWS
PsychoGenics Highlights a Long-term Collaboration with the TSC Alliance on Rare Disease Day
February 28, 2023
INDUSTRY NEWS
The Next Generation of Antidepressants and Antipsychotics
February 24, 2023
PUBLICATION
Immunotherapy Targeting the C-Terminal Domain of TDP-43 Decreases Neuropathology and Confers Neuroprotection in Mouse Models of ALS/FTD
February 20, 2023
INDUSTRY NEWS
2023 Pharma Predictions
February 9, 2023
INDUSTRY NEWS
PsychoGenics CEO Explores CNS Drug Development Trends
February 4, 2023
INDUSTRY NEWS
What Will the 2023 Drug Discovery Landscape Look Like?
January 24, 2023
Optimization and validation of profiling efforts within the NINDS preclinical screening platform for pain (PSPP) to accelerate the development of novel non-opioid, non-addictive pain therapeutics
January 13, 2023